Clinical Trials Logo

Cognition Disorders clinical trials

View clinical trials related to Cognition Disorders.

Filter by:

NCT ID: NCT01686698 Completed - Cirrhosis Clinical Trials

Effect of VSL#3 (Original De Simone Formulation) on Cognitive Function, Risk of Falls and Quality of Life in Patients With Cirrhosis

Start date: March 2013
Phase: Phase 4
Study type: Interventional

Probiotics, due to their ability to modulate intestinal flora, intestinal permeability and immune response, could decrease bacterial translocation and improve immune system alterations in cirrhosis. This could lead not only to improvement in liver function and to prevent bacterial infections and other complications but also to improve CD and to avoid its consequences falls, HRQoL deterioration). Recently, the investigators have observed that VSL#3 administration to rats with experimental cirrhosis decreases bacterial translocation, inflammatory response and ascites formation, without changes in intestinal flora. This suggests an improvement in intestinal barrier that deserves further investigation. VSL#3, through decreasing intestinal bacterial translocation and immune system modulation, could improve cognitive function and prevent the consequences of CD, including falls and HRQoL deterioration, in patients with cirrhosis.

NCT ID: NCT01678755 Completed - Schizophrenia Clinical Trials

A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

Start date: August 2012
Phase: Phase 2
Study type: Interventional

This is an efficacy study evaluating a experimental treatment for cognitive deficits in adults with schizophrenia.

NCT ID: NCT01672827 Completed - Clinical trials for Mild Cognitive Impairment

Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images

Start date: July 2012
Phase: Phase 3
Study type: Interventional

To Evaluate the Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]flutemetamol Positron Emission Tomography (PET) Images.

NCT ID: NCT01668758 Withdrawn - Cognition Disorder Clinical Trials

fMRI and NIRS Imaging for Traumatic Brain Injury

Start date: July 25, 2012
Phase: N/A
Study type: Observational

Background: - The amount of blood flowing in brain areas goes up when those areas are being used for activities, such as movement or seeing. Functional magnetic resonance imaging (fMRI) is a common way of measuring blood flow in the brain. Near infrared spectroscopy (NIRS) can also be used to study blood flow in the brain. However, NIRS has not been used as often as fMRI. Researchers want to compare fMRI and NIRS to see whether they give similar results. These studies will be used to look at people who have had a traumatic brain injury. Objectives: - To test how well NIRS measure changes in blood flow in the brain after a traumatic brain injury. Eligibility: - Individuals between 18 and 60 years of age who have had a traumatic brain injury. - Healthy volunteers at least 18 years of age. Design: - Participants will be screened with a physical exam and medical history. Researchers may ask to see brain images during from previous MRI scans. - Participants will have a NIRS scan of the brain. They will be asked to do certain tasks while inside the scanner. These tasks will involve responding to images that appear on a screen. - Treatment will not be provided as part of this study.

NCT ID: NCT01667484 Completed - Multiple Sclerosis Clinical Trials

Adderall XR and Processing Speed in Multiple Sclerosis (MS)

Start date: September 2012
Phase: Phase 2/Phase 3
Study type: Interventional

Cognitive impairment, or problems with thinking and memory, is common in multiple sclerosis (MS) and can occur independently of physical disability. It is the most common reason, along with physical fatigue, for MS patients to stop working. The most frequent complaint is problems with multi-tasking or thinking quickly, which corresponds to impairment in the cognitive domain of processing speed. Currently there is treatment available to prevent relapses and physical disability but there are no medications that have been shown to treat cognitive impairment. Amphetamines have been beneficial for selective attention and processing speed in attention deficit hyperactivity disorder (ADHD) and traumatic brain injury. This is study will determine whether Adderall XR improves objective measures of processing speed and attention in MS patients impaired in this cognitive domain, by comparing two doses of Adderall XR (5 and 10mg) to placebo before and after the medication is administered. The results of this study will help provide data to design a larger study to determine if Adderall XR, and potentially other amphetamine drugs, will help treat cognitive impairment in MS patients.

NCT ID: NCT01662882 Completed - Clinical trials for Mild Cognitive Impairment

A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Start date: October 2012
Phase: Phase 2/Phase 3
Study type: Interventional

Evaluate florbetapir (18F) positron emission tomography (PET) imaging for distinguishing Japanese healthy control subjects, from Japanese subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).

NCT ID: NCT01661894 Completed - Dementia Clinical Trials

Effectiveness of a Brain-Computer Interface Based System for Cognitive Enhancement in the Normal Elderly

3ECog
Start date: April 2012
Phase: Phase 1
Study type: Interventional

The primary objective is to examine the efficacy of 8-weeks of a locally developed brain-computer interface based system (BrainpalTM)intervention for improving attention and memory in normal elderly. We hypothesize that elderly who have completed the training program will have significant improvement in their attention and memory compared to the controls, based on the Repeatable Battery for the Assessment of Neuropsychological Status.

NCT ID: NCT01661673 Completed - Clinical trials for Mild Cognitive Impairment

Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease

Start date: November 2012
Phase: Phase 2
Study type: Interventional

This study is being conducted to determine the safety, tolerability, pharmacokinetics, and effects of EVP-0962 on cerebral spinal fluid Amyloid concentrations in healthy subjects and in subjects with mild cognitive impairment or early Alzheimer's disease.

NCT ID: NCT01659593 Recruiting - Multiple Sclerosis Clinical Trials

Evaluation of the Efficiency of a Cognitive Remedial Program (PROCOG-SEP) Designed for Multiple Sclerosis Patients

PROCOG-SEP
Start date: September 2012
Phase: N/A
Study type: Interventional

Cognitive disorders are well-known in multiple sclerosis (MS), even in earlier stages of the disease. They effect personal life. Their management may be overlooked. The evidence-based program proposes exercises to both stimulate preserved functions and develop new abilities compensating for cognitive disabilities. Aim of the study is to evaluate the efficiency of the remedial program (PROCOG-SEP) designed for MS patients, compared to an interactive discussion program(DISINT) 140 multiple sclerosis patients will be randomly assigned in one the program for 13 sessions over a 6-month period. Main outcome criteria is evolution of SRT-LIST before and after program.

NCT ID: NCT01659398 Completed - Clinical trials for Mild Cognitive Impairment

Enhanced External Counterpulsation and Its Effects on Vascular Hemodynamics in Cognitively Impaired Patients

Start date: June 2012
Phase: Phase 0
Study type: Interventional

The aim of this study is to investigate whether enhanced external counterpulsation (EECP) therapy for 7 consecutive weeks will improve cerebral blood flow and possibly over time enhance or slow down breakdown of cognitive function in patients diagnosed with mild cognitive impairment (MCI).